Bristol Myers Squibb and Cellares, a development and manufacturing organization dedicated to clinical and industrial-scale cell therapy manufacturing, announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments. As part of the agreement, Cellares will optimize, automate, and tech-transfer select Bristol Myers Squibb CAR T cell therapies onto its automated and high-throughput manufacturing platform, the Cell Shuttle. Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use. The Cell Shuttles and Cell Qs will be deployed in Cellares’ Smart Factories in the U.S., EU, and Japan. This agreement expands upon the existing collaborations between Bristol Myers Squibb and Cellares. In August 2023, Bristol Myers Squibb participated in Cellares’ Series C financing to launch the first IDMO Smart Factory in an effort to meet the demand for cell therapies globally. That same month, Bristol Myers Squibb joined Cellares’ Technology Adoption Partnership Program to evaluate the Cell Shuttle’s automated manufacturing capabilities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
- Bristol Myers price target raised to $52 from $51 at Wells Fargo
- Bristol Myers: Krazati plus cetuximab showed ORR of 34%, PFS of 6.9 months
- Bristol Myers presents new data from Phase 3 EMERGENT program evaluating KarXT
- Bristol Myers presents new interim long-term efficacy data from EMERGENT-4 trial